Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06698484 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Study acronym: CAR-T for NHL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 21, 2024 (before its estimated June 2, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Trial Details
NCT Number NCT06698484
Lead Sponsor National University of Malaysia
Collaborators: Plutonet Sdn Bhd
Conditions
(from sponsor)		 Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Related terms Lymphoma, B-Cell
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov